WhiteOak Capital Pharma and Healthcare Fund Direct Growth NAV today
AMFI: 152349ISIN: INF03VN01886MUTF_IN: WHIT_CAPI_PHRM_2LAJK3WhiteOak Capital Mutual FundSectoral / Thematic funds
NAV ₹16.2190down ₹0.15 (0.92%)
NAV for 23 Oct 2026, against 22 Oct 2026. Declared once a day.
- Fund sizeAssets under management. The money the fund manages for all its investors, across every plan, at the end of the month.
- ₹927 CrSep 2026
- Expense ratioTotal expense ratio. What the fund charges each year as a share of the money invested, taken out of the NAV every day, so the returns shown are already after it.
- 1.07%19 Oct 2026
- Exit loadExit load. A charge, as a share of the amount redeemed, on units sold before a set period has passed since they were bought.
- None
- P/EP/E. What the fund pays for each rupee of yearly profit its companies earn: the total value of its shares divided by those companies' last four quarters of profit, each in proportion to what the fund holds. The profit leaves out one-off items (exceptional items and businesses sold or demerged), so one company's one-off gain cannot make the fund look cheap. A loss-making company lowers the profit. Shown when at least 80% of the fund's shares are counted.
- 51.530 Sep 2026
- Risk levelRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month.
- Very HighAug 2026
- HoldingsHoldings. The number of different securities in the fund's latest monthly portfolio: shares, bonds, money market paper and units of other funds, not cash, overnight lending or futures.
- 5930 Sep 2026
- LaunchedLaunch date. The day the fund first allotted units to investors, at the close of its new fund offer.
- 6 Feb 2024
WhiteOak Capital Pharma and Healthcare Fund returns
Direct Growth plan
Over each window to 23 Oct 2026
| Over | ReturnTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). | BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back. | Rank in categoryRank in category. The fund's place among the funds of its category with a return over the same window, highest return first. | Category medianCategory median. The middle return of the funds in the category over the same window: half returned more, half less. | Middle halfMiddle half of the category. The returns of the fund a quarter of the way down the category and the fund a quarter of the way up, over the same window: half the category's funds returned between the two. |
|---|---|---|---|---|---|
| 1 week | −2.46% | – | – | – | – |
| 1 month | −9.75% | – | 203 of 254 | −8.23% | −9.5% to −6.6% |
| 3 months | −3.35% | – | 48 of 250 | −6.23% | −7.7% to −4.3% |
| 6 months | +11.21% | – | 11 of 250 | −3.43% | −6.3% to +2.1% |
| 1 year | +10.95% | +16.77%to 30 Sep 2026 | 13 of 228 | −5.19% | −9.3% to +0.6% |
| 3 years | Needs 3 years | – | – | +12.40% | +8.6% to +16.8% |
| 5 years | Needs 5 years | – | – | +10.89% | +8.1% to +14.6% |
| 10 years | Needs 10 years | – | – | +13.74% | +11.5% to +15.5% |
₹10,000 put in on 7 Feb 2024 is ₹16,101 at the NAV of 23 Oct 2026Growth of ₹10,000. What ₹10,000 put in at the NAV of the first day would be worth at the latest NAV, after the fund's expenses and before tax and any exit load.Over a year and longer, a return is the yearly rate. Benchmark: BSE Healthcare TRI, over the same days as the fund, or to the month end its cell names. Rank, median and middle half among the Direct plans of Sectoral / Thematic funds, each fund's return to its latest NAV on or before 25 Oct 2026.
At the month end, 30 Sep 2026
| Over | FundTrailing return. The change in NAV from the start date to the latest NAV; over a year and longer, the yearly rate that would compound to the same change (CAGR). | BenchmarkBenchmark return. The change in the benchmark index's total return level over the same dates as the fund's return, as a yearly rate over a year and longer. |
|---|---|---|
| 1 year | +24.16% | +16.77% |
| Since launch | +22.94% | +15.53% |
Benchmark: BSE Healthcare TRI. Both as the fund house states them for the month.
Return in each calendar year
- Fund, Direct GrowthCalendar year return. The change in NAV from the last NAV of one year to the last NAV of the next.
WhiteOak Capital Pharma and Healthcare Fund SIP returns
₹10,000 on the 1st of every month, valued at the NAV of 23 Oct 2026
| Period | InvestedAmount invested. ₹10,000 on the 1st of every month, or the next day the fund priced, added up over the period. | Value todayValue today. What the units bought by every instalment are worth at the latest NAV. | Invested against value today | SIP returnSIP return (XIRR). The yearly rate that, applied to each monthly instalment from the day it was invested, gives the value of all the units today. | After stamp dutySIP return after stamp duty. The same SIP return with stamp duty of 0.005% taken from every instalment since 1 Jul 2020, so ₹10,000 buys ₹9,999.50 of units. | Stamp dutyStamp duty paid. The stamp duty on all the instalments, in rupees: 0.005% of each purchase made since 1 Jul 2020. |
|---|---|---|---|---|---|---|
| 1 year12 instalments | ₹1,20,000 | ₹1,27,590₹1,27,584 after stamp duty | +12.48% | +12.47% | ₹6 | |
| Since Feb 202432 instalments | ₹3,20,000 | ₹3,90,861₹3,90,841 after stamp duty | +15.44% | +15.44% | ₹16 |
3 years: Launched 6 Feb 2024, needs 3 years of history.
Rolling returns
Per cent a year, every window from 7 Feb 2024 to 23 Oct 2026
Lowest to highestAverage
LowestLowest rolling return. The worst yearly return of any window of this length in the fund's history, one window starting on each day it priced.AverageAverage rolling return. The average of the yearly returns of every window of this length in the fund's history.HighestHighest rolling return. The best yearly return of any window of this length in the fund's history.Ended higherWindows that ended higher. The share of all the windows of this length in which the NAV ended above where it started.
1 year421 windows+0.6%+17.9%+35.5%100.0%
3 yearsLaunched 6 Feb 2024, needs 4 years of history
Every 1-year window ended higher than it started.
WhiteOak Capital Pharma and Healthcare Fund expense ratio and exit load
Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.
- Regular over directDirect and regular plan cost gap. The regular plan's expense ratio less the direct plan's: what buying through a distributor costs each year, since both plans own the same portfolio.
- 1.67 ptsA year, on 19 Oct 2026
- Direct, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies.
- 1.07%Over the last 30 days filed
- Regular, 30-day averageExpense ratio, 30-day average. The total expense ratio averaged over the last 30 days the fund filed it, which evens out the day-to-day moves in brokerage and levies.
- 2.74%Over the last 30 days filed
Total expense ratio, month by month
- Regular plan
- Direct plan
Direct plan highest 1.28%, Jun 2026.Direct plan lowest 0.55%, Mar 2025.
What the expense ratio is made of
| Part | Direct | Regular |
|---|---|---|
| Base expense ratioBase expense ratio. The part of the expense ratio that pays the fund house and the distributor, before brokerage, transaction costs, levies and GST. | 0.54% | 1.96% |
| Brokerage | 0.12% | 0.12% |
| Transaction costs | 0.01% | 0.01% |
| Statutory levies | 0.40% | 0.65% |
Per cent of assets a year, filed for 19 Oct 2026. The parts add up to that day's total.
Buying and selling
- Lump-sum purchases
- Accepted
- Minimum investmentMinimum investment. The smallest amount the plan accepts for a first purchase.
- ₹500
- Minimum top-up
- ₹500
- Minimum redemption
- ₹500
- SIP
- Accepted
- STP, transfers to another fund
- Not accepted
- SWP, regular withdrawals
- Accepted
- Switches
- Accepted
- Lock-inLock-in. The time after each purchase during which those units cannot be sold.
- None
- SIP minimum
- Daily/Weekly/Fortnightly/Monthly - Rs.100, Quarterly - Rs. 500
- SIP instalments, at least
- Daily/Weekly/Fortnightly/Monthly - 6, Quarterly - 4
- SIP dates
- Daily - All business days, Weekly - Any day from Monday to Friday (Monday will be the default day), Fortnightly - 1st and 16th day of each month, as applicable (1st and 16th of the month will be the default dates), Monthly - Any date of every month (between 1st & 28th) (10th will be the default date), Quarterly - Any date of every quarter (between 1st & 28th)
As listed for this plan on 24 Oct 2026.
WhiteOak Capital Pharma and Healthcare Fund AUM
₹ crore, every plan of the fund together.
- Average assetsAverage assets under management. The money the fund managed, averaged over every day of the quarter, added up across its plans.
- ₹858 CrQuarter to Sep 2026
- In the direct plansShare of assets in the direct plans. The direct plans' average assets for the quarter as a percentage of the fund's total; the rest is in the regular plans, bought through distributors.
- 21.3%Of the quarter's average
Average assets by quarter, by plan
- Regular plans
- Direct plans
The latest quarter is the largest since the quarter to Mar 2024.
Assets at each month end
The latest month end is the highest since Feb 2025.Lowest ₹271 Cr, Feb 2025.
WhiteOak Capital Pharma and Healthcare Fund portfolio
Portfolio disclosed for 30 Sep 2026.
Holdings on 30 Sep 2026
| Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month. | Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | Held since. The first month end of the fund's current run of holding this position; marked "or earlier" where that month is the fund's first portfolio on record or the first after a gap in its portfolios. | ||||
|---|---|---|---|---|---|---|
| Divi's LaboratoriesPharmaceuticals & Biotechnology | Shares | Large cap50th | 8.36% | 77.50 | 83,411 | Apr 2024 |
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | Shares | Large cap13th | 7.11% | 65.86 | 3,62,534 | Feb 2024or earlier |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | Shares | Large cap61st | 6.26% | 58.00 | 1,20,829 | Jul 2026 |
| Laurus LabsPharmaceuticals & Biotechnology | Shares | Mid cap171st | 3.91% | 36.24 | 1,83,009 | Oct 2024 |
| Apollo Hospitals EnterpriseHealthcare Services | Shares | Large cap97th | 3.75% | 34.78 | 42,590 | Jul 2024 |
| CiplaPharmaceuticals & Biotechnology | Shares | Large cap99th | 3.68% | 34.07 | 2,53,088 | May 2026 |
| Sai Life SciencesPharmaceuticals & Biotechnology | Shares | Small cap329th | 3.28% | 30.37 | 1,99,211 | Jun 2025 |
| IPCA LaboratoriesPharmaceuticals & Biotechnology | Shares | Mid cap229th | 2.88% | 26.65 | 1,38,311 | Jan 2026 |
| Zydus LifesciencesPharmaceuticals & Biotechnology | Shares | Mid cap114th | 2.81% | 26.07 | 2,24,351 | Feb 2026 |
| Neuland LaboratoriesPharmaceuticals & Biotechnology | Shares | Small cap356th | 2.60% | 24.08 | 11,278 | Feb 2024or earlier |
| Dr. Lal Path LabsHealthcare Services | Shares | Small cap309th | 2.35% | 21.76 | 1,09,504 | Feb 2026 |
| CORONA RemediesPharmaceuticals & Biotechnology | Shares | Small cap566th | 2.34% | 21.64 | 1,03,396 | Dec 2025 |
| Thyrocare TechnologiesHealthcare Services | Shares | Small cap673rd | 2.27% | 21.07 | 3,94,514 | Oct 2024 |
| Aurobindo PharmaPharmaceuticals & Biotechnology | Shares | Mid cap138th | 2.09% | 19.39 | 1,15,954 | Feb 2026 |
| Ajanta PharmaPharmaceuticals & Biotechnology | Shares | Mid cap236th | 2.01% | 18.63 | 51,455 | Feb 2024or earlier |
Weight is per cent of the fund's net assets; value in ₹ crore.
Futures and options on 30 Sep 2026
| Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | |||
|---|---|---|---|
| Dr. Reddy's Laboratories Limited | 2.07% | 19.18 | 1,56,250 |
| Cipla Limited | 1.86% | 17.19 | 1,26,650 |
| Aurobindo Pharma Limited | 1.56% | 14.48 | 86,350 |
| Laurus Labs Limited | 1.41% | 13.05 | 65,450 |
| Mankind Pharma Limited | 1.12% | 10.38 | 41,500 |
| Apollo Hospitals Enterprise Limited | 0.21% | 1.93 | 2,375 |
Weight is per cent of the fund's net assets; value in ₹ crore.
Cash and receivables on 30 Sep 2026
| Weight in the fund. The holding's market value on the portfolio date as a share of the fund's net assets. | ||
|---|---|---|
| Clearing Corporation of India Ltd | 5.55% | 51.47 |
| Net Receivables / (Payables) | 0.58% | 5.27 |
Weight is per cent of the fund's net assets; value in ₹ crore.
- Largest holdingLargest holding. The share of the fund in its single largest position, cash and futures not counted as positions.
- 8.36%Divi's Laboratories
- Top 5 holdingsTop 5 holdings. The share of the fund held in its five largest positions.
- 29.39%
- Top 10 holdingsTop 10 holdings. The share of the fund held in its ten largest positions.
- 44.64%
- Effective holdingsEffective number of holdings. The number of equal-sized positions that would be as concentrated as the fund's actual weights.
- 28.7Taken over 93.87% of the fund
Asset allocation
Asset allocation. What the fund owns, by kind of asset, each as a share of its net assets; futures and options are shown beside it, not in it, since they are contracts rather than assets bought.- Indian shares90.72%
- Bonds and bills3.15%
- Cash and receivables6.13%
- Futures and options, netFutures and options, net. The value of the shares or bonds the fund's contracts are written on, as a share of its net assets, a sold contract counted as a minus: a hedged fund's sold futures offset the shares it holds.8.23%
- Futures and options, grossFutures and options, gross. The value the fund's contracts are written on, as a share of its net assets, counting each contract as a plus whichever way it faces.8.23%
Per cent of the fund's net assets.
Large, mid and small cap
Large, mid and small cap. Companies ranked by average market value over six months: the first 100 are large cap, the next 150 mid cap, the rest small cap, by the list in force for the portfolio's month.- Large cap32.14%Category 49.50%
- Mid cap23.92%Category 21.62%
- Small cap42.10%Category 26.68%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026. Shares not on the list: 1.67% of the fund. Category is the average of 249 Sectoral / Thematic funds.
Sector allocation
Sector weight. The fund's shares grouped by the business each company is in, less the futures sold on them, each group as a share of the fund's net assets.3sectors
- Healthcare91.70%Category 12.70%
- Chemicals3.34%Category 1.97%
- Consumer Durables1.84%Category 3.48%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026. Category is the average of 254 Sectoral / Thematic funds. Category average. The sector's weight, less the futures sold on it, averaged over the 254 Sectoral / Thematic funds that disclosed a portfolio for Sep 2026. A fund holding none of the sector counts as 0.
Sector allocation month by month
| 13 months | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Healthcare45 companies | 91.70% | 93.95% | 94.07% | 93.71% | 93.58% | 91.90% | 92.81% | 92.13% | 91.91% | 93.22% | 93.30% | 96.28% | |
| Chemicals4 companies | 3.34% | 3.36% | 3.77% | 3.27% | 2.99% | 3.98% | 3.67% | 3.81% | 3.91% | 3.32% | 3.49% | 0.85% | |
| Consumer Durables1 company | 1.84% | 2.01% | 1.39% | 1.35% | 1.75% | 1.31% | 1.58% | 1.78% | 1.90% | 2.07% | 2.10% | 1.19% | |
| Financial Services | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Capital Goods | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Automobile And Auto Components | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Consumer Services | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Information Technology | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Fast Moving Consumer Goods | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Oil Gas & Consumable Fuels | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Telecommunication | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Power | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Oct 2025 to Sep 2026; the line runs from Sep 2025.
Bought and sold
Sep 2026 against Aug 2026, position by position.
Positions changed, month by month
- New
- Added
- Trimmed
- Sold out
- New positionsNew positions. Holdings in this month's portfolio that were not in the month before.
- 76.82% of the fund
- Sold outSold out. Holdings in last month's portfolio that are gone from this one, other than a bond or deposit repaid on its due date.
- 52.58% of the fund before
- MaturedMatured. Bonds and deposits whose repayment date fell between the two portfolios, so they were repaid rather than sold. One sold in its last days reads the same.
- 2
- Added toAdded to. Holdings with more units than the month before. Where the fund states no units, a weight that rose by more than a tenth.
- 14
- TrimmedTrimmed. Holdings with fewer units than the month before. Where the fund states no units, a weight that fell by more than a tenth.
- 4
- UnchangedUnchanged. Holdings with the same number of units as the month before. Their weight can still move with the price.
- 40
- Traded at leastTraded at least. The smaller of the weight bought in new positions and the weight sold out of old ones, cash left out: the least the fund must have bought and sold in the month.
- 2.58%
- Weight that movedWeight that moved. Half the sum of every position's change in weight between the two month ends, new and sold positions included; price moves alone raise it.
- 10.43%
Changes in Sep 2026
| What changed. New: not held the month before. Added or trimmed: more or fewer units than the month before, or, where no units are stated, a weight that moved by more than a tenth. Sold out: held the month before, gone now. Matured: a bond or deposit whose repayment date fell between the two portfolios, so it was repaid rather than sold (one sold in its last days reads the same). | Change in weight. The holding's weight this month less its weight the month before, in percentage points; a price move alone changes it. | ||||
|---|---|---|---|---|---|
| Max Healthcare Institute | Trimmed | 1.84% | 3.05% | −1.21 pts | −80,222 |
| Mankind Pharma | New | 1.20% | 0.00% | +1.20 pts | +44,418 |
| Pfizer | Sold out | – | 1.14% | −1.14 pts | −21,935 |
| Piramal Pharma | New | 1.06% | 0.00% | +1.06 pts | +4,75,297 |
| Apollo Hospitals Enterprise | Trimmed | 3.75% | 4.73% | −0.98 pts | −5,392 |
| Poly Medicure | Sold out | – | 0.76% | −0.76 pts | −38,962 |
| Manipal Health Enterprises | Trimmed | 0.52% | 1.15% | −0.63 pts | −67,800 |
| 91 Days Tbill (MD 03/12/2026) | New | 0.60% | 0.00% | +0.60 pts | +5,60,000 |
| Onesource Specialty Pharma | Added | 1.55% | 1.01% | +0.54 pts | +34,383 |
| 91 Days Tbill (MD 10/12/2026) | New | 0.53% | 0.00% | +0.53 pts | +5,00,000 |
| Cipla | Added | 3.68% | 3.25% | +0.43 pts | +44,727 |
| 91 Days Tbill (MD 03/09/2026) | Matured | – | 0.33% | −0.33 pts | – |
| Ajanta Pharma | Added | 2.01% | 1.72% | +0.29 pts | +8,434 |
| Sun Pharmaceutical Industries | Added | 7.11% | 7.40% | −0.29 pts | +26,263 |
| Novartis India | New | 0.24% | 0.00% | +0.24 pts | +11,712 |
Weights are per cent of the fund's net assets; a change in weight is in percentage points. Securities only: 4 futures, options and cash lines that changed are not listed.
Holdings month by month
| Holding | Oct 25 | Nov 25 | Dec 25 | Jan 26 | Feb 26 | Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 Divi's Laboratories | 6.87%Added | 3.33%Cut | 4.50%Added | 5.48%Added | 4.74%Cut | 5.31%Added | 4.11%Cut | 3.29%Cut | 1.68%Cut | 3.86%Added | 8.45%Added | 8.36%Added |
 Sun Pharmaceutical Industries | 7.82%Added | 8.31%Added | 10.91%Added | 10.72%Added | 11.85%Added | 12.35%Added | 10.47%Cut | 9.56%Added | 8.66%Cut | 8.53%Added | 7.40%Cut | 7.11%Added |
 Torrent Pharmaceuticals | – | – | – | – | 0.29%Bought again | Sold out | – | – | – | 7.81%Bought again | 6.78%Cut | 6.26% |
 Laurus Labs | 4.68%Added | 4.94%Added | 5.44%Added | 4.41%Cut | 4.33%Cut | 3.93%Added | 4.13%Added | 4.43%Cut | 4.61%Added | 4.94%Cut | 3.78%Cut | 3.91%Added |
 Apollo Hospitals Enterprise | 1.48%Cut | 1.35% | 1.77%Added | 4.90%Added | 5.08% | 4.24%Cut | 4.02% | 4.83%Added | 4.59% | 4.78%Added | 4.73%Added | 3.75%Cut |
 Cipla | 4.20% | 3.80%Cut | 3.90%Added | 0.80%Cut | Sold out | – | – | 0.69%Bought again | 3.25%Added | 3.72%Added | 3.25% | 3.68%Added |
 Sai Life Sciences | 2.94%Added | 2.61%Cut | 2.16%Cut | 2.05% | 2.46%Added | 2.77%Added | 3.02%Added | 3.17%Added | 3.22%Added | 3.18%Added | 3.32%Added | 3.28%Cut |
 IPCA Laboratories | – | – | – | 0.78%Bought again | 1.96%Added | 2.17%Added | 1.02%Cut | 0.92% | 0.92% | 1.12%Added | 2.66%Added | 2.88%Added |
 Zydus Lifesciences | – | – | – | – | 0.49%Bought again | 0.83%Added | 1.14%Added | 1.61%Added | 2.21%Added | 2.94%Added | 2.58%Cut | 2.81%Added |
 Neuland Laboratories | 3.82%Added | 3.09%Cut | 2.49%Cut | 2.25% | 1.46%Cut | 1.42%Added | 2.64%Added | 2.53%Cut | 2.47% | 2.87%Added | 2.88%Cut | 2.60% |
 Dr. Lal Path Labs | – | – | – | – | 1.17%Bought again | 1.34%Added | 1.29% | 2.11%Added | 1.94% | 2.53%Added | 2.35% | 2.35% |
 CORONA Remedies | – | – | 0.51%Bought | 2.03%Added | 2.31%Added | 2.27%Added | 2.43%Added | 2.32%Added | 2.54%Added | 2.44% | 2.35%Added | 2.34% |
 Thyrocare Technologies | 2.16%Added | 1.21%Cut | 1.29%Added | 1.03%Cut | 0.99%Added | 1.56%Added | 1.98%Added | 2.06%Cut | 2.10%Added | 2.20%Added | 2.31%Added | 2.27%Added |
 Aurobindo Pharma | – | – | – | – | 1.32%Bought again | 3.02%Added | 3.33%Added | 2.62%Cut | 2.69%Added | 2.42% | 2.21%Cut | 2.09% |
 Ajanta Pharma | 1.95%Added | 2.03%Added | 2.27%Added | 2.56%Added | 2.35%Cut | 2.11% | 1.78%Cut | 1.68% | 1.65%Cut | 1.81%Added | 1.72% | 2.01%Added |
Per cent of the fund's net assets at each month end, Oct 2025 to Sep 2026. Under it, the change on the fund's previous month. "After a gap" is a holding after a month with no portfolio on record, so when it was bought is not known; "Not filed" is one gone across such a gap.
Portfolio turnover, per cent of assets a year
- TurnoverPortfolio turnover. How much of the portfolio the fund bought or sold over the last year, as a share of its assets, as the fund house states it.
Highest 204.0% in May 2026
Risk ratios
NAV to 23 Oct 2026
Each bar runs from the lowest to the highest figure among the Direct plans of Sectoral / Thematic funds (227 funds) over the same 1 year; the tick is their average and the dot this fund.
How much the NAV moves
Standard deviationStandard deviation. How far the fund's monthly returns spread around their average, stated as a yearly figure: the wider the spread, the more the NAV moves.15.46%
12.44%Lowest20.07%Average46.96%Highest
Downside deviationDownside deviation. Standard deviation counting only the months in which the fund lost money, stated as a yearly figure.7.87%
4.39%Lowest13.32%Average21.46%Highest
Sharpe ratioSharpe ratio. The monthly return above the 91-day Treasury bill yield, divided by its standard deviation and stated for a year: the extra return for each unit of movement in the NAV.1.14
−1.29Lowest0.07Average1.84Highest
Sortino ratioSortino ratio. The monthly return above the 91-day Treasury bill yield, divided by how far it fell below that yield and stated for a year: the extra return for each unit of movement on the way down.2.02
−1.42Lowest0.20Average4.31Highest
Against BSE Healthcare TRI
BetaBeta. How much the fund's monthly return moved for each 1% move in its benchmark: 1 moves with it, below 1 moves less.1.01
0.55Lowest0.97Average of 218 funds1.47Highest
R-squaredR-squared. The share of the fund's monthly movement that its benchmark's movement explains, from 0 to 100.97.0
27.0Lowest89.5Average of 218 funds99.3Highest
CorrelationCorrelation. How closely the fund's monthly returns moved in step with its benchmark's, from minus 1 (always opposite) to 1 (always together).0.98
0.52Lowest0.94Average of 218 funds1.00Highest
Upside captureUpside capture. The fund's return in the months its benchmark rose, as a percentage of the benchmark's return in those months.118.2%
59.0%Lowest107.5%Average of 185 funds182.4%Highest
Downside captureDownside capture. The fund's return in the months its benchmark fell, as a percentage of the benchmark's fall in those months.Needs 6 falling months
Information ratioInformation ratio. The fund's return above its benchmark, divided by how much that difference varied, as stated by the fund house.To 30 Sep 20261.70
Largest falls
| Largest over | FallLargest fall. The biggest drop in NAV from a high to the low that followed, before the NAV went back above that high. | High on | Low on | Back at the highBack at the high. The first day the NAV closed at or above the high it had fallen from. |
|---|---|---|---|---|
| 1 year | −9.75% | 23 Sep 2026 | 23 Oct 2026 | Not yet |
| Since Feb 2024 | −15.39% | 2 Jan 2025 | 28 Feb 2025 | 14 Jul 2025 |
Risk level by month
| Months | FundRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month. | BenchmarkBenchmark's risk level. The riskometer level of the fund's benchmark index for the same month, on the same six-step scale as the fund's own. |
|---|---|---|
| Mar 2025 to Aug 202618 months | Very High | Very HighBSE Healthcare TRI |
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.
WhiteOak Capital Pharma and Healthcare Fund managers
Managers now
| Manager | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. | Portfolio changed after the handover. How much of the portfolio was different three months after the manager took over: half the sum of every holding's change in weight, with each side's holdings scaled to add up to 100 so a move into cash does not count. | Portfolio changed before the handover. The same measure over the three months before the manager took over, since portfolios change anyway. | Assets the manager runs. The latest monthly size of every fund the manager runs now, added up; a fund run with others counts in full for each of its managers, and the line under it counts only the funds they run alone. | ||
|---|---|---|---|---|---|---|---|---|
| Ramesh MantriComanage/Equity | Feb 2024 | +20.48%a year | – | – | – | – | 20 | ₹45,527 Cr |
| Piyush BaranwalComanage/Debt | Feb 2024 | +20.48%a year | – | – | – | – | 22 | ₹46,803 Cr₹1,276 Cr alone |
| Dheeresh PathakAssistant Fund Manager - Equity | Feb 2024 | +20.48%a year | – | – | – | – | 19 | ₹42,904 Cr |
| Ashish AgrawalFund Manager - Arbitrage Transactions | Jan 2025 | +10.65%a year | – | – | 23.3% | 35.1% | 20 | ₹45,527 Cr |
| Trupti AgrawalAssistant Fund Manager - Equity | May 2025 | +18.59%a year | – | – | 38.5% | 22.1% | 19 | ₹42,904 Cr |
Returns are the direct plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.
Other funds they run
| Fund | Return in the manager's time. The change in the plan's NAV from the day the manager took the fund over to the latest NAV; past a year, the yearly rate that would compound to the same change. | Benchmark over the same days. The change in the fund's benchmark index over the same days as the manager's return, worked out the same way, with the dividends of the index's companies added back. | Difference from the benchmark. The fund's return in the manager's time less its benchmark's over the same days, in percentage points. | ||
|---|---|---|---|---|---|
| WhiteOak Capital Flexi Cap FundRamesh Mantri | Aug 2022 | +15.70%a year | – | – | ₹9,325 Cr |
| WhiteOak Capital Multi Asset Allocation FundRamesh Mantri | May 2023 | +15.68%a year | – | – | ₹9,111 Cr |
| WhiteOak Capital Mid Cap FundRamesh Mantri | Sep 2022 | +21.51%a year | – | – | ₹7,540 Cr |
| WhiteOak Capital Multi Cap FundRamesh Mantri | Sep 2023 | +17.36%a year | +11.09% | +6.27 pts | ₹4,308 Cr |
| WhiteOak Capital Arbitrage FundRamesh Mantri | Sep 2024 | +7.23%a year | – | – | ₹2,623 Cr |
| Whiteoak Capital Large & Mid Cap FundRamesh Mantri | Dec 2023 | +11.99%a year | – | – | ₹2,376 Cr |
| WhiteOak Capital Balanced Advantage FundRamesh Mantri | Feb 2023 | +12.55%a year | – | – | ₹2,256 Cr |
| WhiteOak Capital Special Opportunities FundRamesh Mantri | May 2025 | +12.31%a year | – | – | ₹1,959 Cr |
| WhiteOak Capital Large Cap FundRamesh Mantri | Dec 2022 | +11.76%a year | – | – | ₹1,208 Cr |
| WhiteOak Capital Banking & Financial Services FundRamesh Mantri | Feb 2024 | +10.40%a year | +9.53% | +0.88 pts | ₹626 Cr |
Up to ten funds a manager, largest first. Returns are the direct plan's.
Portfolio overlap
Funds holding the most of the same securities, by weight.
Closest funds in the category
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. | Shared holdings. The number of securities both funds hold, cash and futures left out. | |
|---|---|---|
| SBI Healthcare Opportunities FundSBI Mutual Fund | 57.57% | 27 |
| Mirae Asset Healthcare FundMirae Asset Mutual Fund | 53.80% | 20 |
| ITI Pharma and Healthcare FundITI Mutual Fund | 53.61% | 22 |
| Kotak Healthcare FundKotak Mahindra Mutual Fund | 53.02% | 23 |
| Bajaj Finserv Healthcare FundBajaj Finserv Mutual Fund | 52.20% | 21 |
| PGIM India Healthcare FundPGIM India Mutual Fund | 51.37% | 22 |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 51.30% | 23 |
| Aditya Birla Sun Life Pharma and Healthcare FundAditya Birla Sun Life Mutual Fund | 49.69% | 23 |
| Baroda BNP Paribas Health and Wellness FundBaroda BNP Paribas Mutual Fund | 48.24% | 19 |
| Nippon India Pharma FundNippon India Mutual Fund | 47.34% | 20 |
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.
Overlap with the fund house's other funds
| Portfolio overlap. The share of the two funds' portfolios that is the same: for every holding they share, the smaller of its two weights, added up. | |
|---|---|
| WhiteOak Capital Multi Cap FundWhiteOak Capital Mutual Fund | 14.16% |
| WhiteOak Capital Mid Cap FundWhiteOak Capital Mutual Fund | 13.65% |
| WhiteOak Capital Quality Equity FundWhiteOak Capital Mutual Fund | 13.59% |
| Whiteoak Capital Large & Mid Cap FundWhiteOak Capital Mutual Fund | 12.52% |
| WhiteOak Capital Flexi Cap FundWhiteOak Capital Mutual Fund | 11.91% |
| WhiteOak Capital Special Opportunities FundWhiteOak Capital Mutual Fund | 10.88% |
| WhiteOak Capital ELSS Tax Saver FundWhiteOak Capital Mutual Fund | 10.54% |
| WhiteOak Capital ESG Best-In-Class Strategy FundWhiteOak Capital Mutual Fund | 9.93% |
| WhiteOak Capital Consumption Opportunities FundWhiteOak Capital Mutual Fund | 8.10% |
| WhiteOak Capital Large Cap FundWhiteOak Capital Mutual Fund | 6.51% |
As the fund house states it, for Sep 2026.
Changes to the fund
Newest first.
2026
- 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top
Fund details
Objective
To provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.
Asset allocation
- Equity & Equity related Instruments of Pharma and Healthcare companies: 80% - 100%;
- Equity and Equity Related Instruments companies (including REITs) other than above: 0% - 20%;
- Money Market Instruments##, Other Liquid Instruments^, Gold and Silver ETFs and units of Domestic Mutual Fund Schemes@: 0% - 20%;
- Units issued by InvITs: 0% - 10%
##Money market instruments include commercial papers, commercial bills, treasury bills, Government securities having an unexpired maturity up to one year, call or notice money, certificate of deposit, usance bills, and any other like instruments as specified by the Reserve Bank of India.
^Other liquid instruments shall include cash, bank deposits with Scheduled Commercial Banks, Government Securities, Treasury bills, Repo on Government securities and any other instruments as specified by SEBI. @Units of domestic mutual fund schemes are permitted only in Overnight funds, Liquid funds and Money Market funds. As per Para 3.8.1.c of SEBI Master Circular on Mutual Funds dated March 20, 2026, the Scheme will invest residual portion in equity and equity related instruments, money market instruments and other liquid instruments, gold and silver instruments (ETFs) as permitted by SEBI and in InvITs, subject to the ceilings laid out in SEBI (Mutual Fund) Regulations, 2026 with respect to the respective asset class.
Type of scheme
An open ended equity scheme investing in Pharma and Healthcare sector.
- Stated category
- Sectoral Fund
- BenchmarkBenchmark. The index the fund house chose to measure the fund against, in its total return form, with dividends added back.
- BSE Healthcare TRI
- Risk level at launchRiskometer. The fund's own risk label on SEBI's six-step scale, from Low to Very High, set from what the fund holds and reviewed every month.
- Very High Risk
- New fund offer
- 16 Jan 2024 to 30 Jan 2024
- Units first allotted
- 6 Feb 2024
- Open for sale again
- 7 Feb 2024
- Price at the offer
- ₹10 a unit
- Minimum at the offer
- ₹500
Plans and codes
| Plan | AMFI code | ISIN | MUTF_IN | First NAV |
|---|---|---|---|---|
| Direct Growth | 152349 | INF03VN01886 | WHIT_CAPI_PHRM_2LAJK3 | 7 Feb 2024 |
| Regular Growth | 152348 | INF03VN01878 | WHIT_CAPI_PHRM_1GKBFME | 7 Feb 2024 |
This fund
- Scheme information document (opens in a new tab)The fund's objective, terms, costs and risks in full
Factsheet
- Factsheet as at September 30, 2026 (opens in a new tab)WhiteOak Capital Mutual Fund, Sep 2026
Statement of additional information
- SAI WhiteOak Capital Mutual Fund (opens in a new tab)WhiteOak Capital Mutual Fund, Oct 2026
Annual report
- WhiteOak Capital Mutual Fund Annual Report 2025-26 (opens in a new tab)WhiteOak Capital Mutual Fund, Jul 2026
- WhiteOak Capital Mutual Fund Abridged Annual Report 2025-26 (opens in a new tab)WhiteOak Capital Mutual Fund, Jul 2026
Riskometer disclosure
- Disclosure of Risk-o-meter - FY 2025-2026 (opens in a new tab)WhiteOak Capital Mutual Fund, Apr 2026
Portfolio overlap disclosure
- Monthly Portfolio Overlap - Sep 30, 2026 (opens in a new tab)WhiteOak Capital Mutual Fund, Sep 2026